Kehua Bio obtains medical device registration certificate

Shanghai Kehua Bio-Engineering (SZSE: 002022) announced that its subsidiary, Suzhou Tianlong Bio-Technology, has received a medical device registration certificate from the National Medical Products Administration for a Hepatitis C Virus (HCV) nucleic acid detection kit (PCR-Fluorescence Method). The registration certificate is valid from March 6, 2025, to March 5, 2030. The product is designed for quantitative detection of HCV nucleic acid (RNA) in human serum or plasma samples. The company expects that this registration will enrich its product line and positively contribute to business development, but notes that it is currently unable to predict the precise impact on future revenue. The company advises investors to pay attention to investment risks.